Paragon Associates & Paragon Associates II Joint Venture Takes $547,000 Position in Quanterix Corporation $QTRX

Paragon Associates & Paragon Associates II Joint Venture acquired a new stake in Quanterix Corporation (NASDAQ:QTRX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 100,671 shares of the company’s stock, valued at approximately $547,000. Quanterix accounts for 1.0% of Paragon Associates & Paragon Associates II Joint Venture’s holdings, making the stock its 12th biggest holding. Paragon Associates & Paragon Associates II Joint Venture owned approximately 0.22% of Quanterix at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of QTRX. R Squared Ltd purchased a new position in Quanterix during the 3rd quarter valued at about $64,000. HUB Investment Partners LLC purchased a new stake in Quanterix during the second quarter worth about $81,000. Brevan Howard Capital Management LP acquired a new stake in shares of Quanterix during the second quarter worth about $96,000. State of Wyoming lifted its position in shares of Quanterix by 105.3% during the second quarter. State of Wyoming now owns 14,814 shares of the company’s stock worth $99,000 after purchasing an additional 7,599 shares in the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of Quanterix by 13.4% in the third quarter. Intech Investment Management LLC now owns 19,161 shares of the company’s stock valued at $104,000 after purchasing an additional 2,268 shares during the period. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Price Performance

QTRX stock opened at $5.06 on Friday. The business’s 50-day moving average is $6.42 and its two-hundred day moving average is $6.01. The firm has a market capitalization of $237.52 million, a P/E ratio of -2.01 and a beta of 1.05. Quanterix Corporation has a 1 year low of $4.05 and a 1 year high of $8.77.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.11). Quanterix had a negative return on equity of 23.96% and a negative net margin of 77.14%.The company had revenue of $41.40 million for the quarter, compared to analyst estimates of $37.95 million. On average, analysts expect that Quanterix Corporation will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on QTRX. Wall Street Zen upgraded shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, December 29th. Canaccord Genuity Group increased their target price on shares of Quanterix from $5.00 to $8.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Quanterix in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Quanterix has a consensus rating of “Hold” and a consensus target price of $11.33.

Quanterix Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.